Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 March 2025 | Story Andre Damons | Photo Andre Damons
Dr Gerard Verhoef
Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys, gave an oral presentation at the second Southern African Mountain Conference.

South Africa is neglecting and overlooking the economic potential of Aloe ferox, forfeiting millions in potential revenue from this ‘green gold’. In doing so, the country is denying farmers and communities the chance to prosper from the land’s true bounty and is also undermining its biodiversity.

While South Africa harvests a mere 200 tons of Aloe ferox annually, its global competitors, such as Mexico, churn out a staggering 400 000 tons of Aloe vera, says Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys. He gave an oral presentation titled IKS, the public domain and Biotrade during a session on Mountain People's Livelihoods at the second Southern African Mountain Conference (SAMC2025).

Researchers, policy makers, and practitioners from across Southern Africa and beyond came together from 17 to 20 March at the scenic Champagne Sports Resort in the central Maluti-Drakensberg for SAMC2025 themed ‘Overcoming Boundaries and Barriers’.

The next rooibos

SAMC2025, under the patronage of UNESCO and organised by the University of the Free State (UFS) Afromontane Research Unit (ARU) – in partnership with the African Mountain Research Foundation (AMRF) and the Global Mountain Safeguard Research Programme (GLOMOS) – delved into critical issues around mountain ecosystems, communities, governance, and transboundary cooperation.

Aloe ferox could be the next rooibos, which is successfully using its geographical indications (GI) status to unlock value throughout the biotrade value chain, Dr Verhoef said. Other South African plants that are also an underutilised asset with economic potential for the country, include honeybush, baobab, umsuzwane, rose geranium, imphepho, Cape chamomile, Kalahari melon, mafura, sour plum, and African ginger.

A GI consists of the name of the place of origin. It links a product to a specific geographical area, which indicates the origin of where the product is produced, processed, or prepared.

Overlooking the potential of Aloe ferox, which has been scientifically proven to contain double the amino acids and 20 times more antioxidants than its international cousin, Aloe vera, Dr Verhoef explains, South Africa is not only undermining its biodiversity but also the economy. Aloe ferox is most popularly used for its laxative effect (aloe bitters) and as a topical application to the skin, eyes, and mucous membranes. It is also used for many traditional uses as well as cosmetic purposes.

Time to capitalise

According to him, Aloe ferox remains an underutilised asset, relegated to niche markets and small-scale production due to regulatory constraints and the unwillingness to obtain access and benefit-sharing (ABC) permits needed to navigate obstacles in South Africa as well as Namibia, Botswana, Zimbabwe, and Mozambique.

“This is not just an agricultural oversight; it is a glaring economic misstep. It is high time that South Africa capitalises on its green gold, turning the tables on international competitors and finally giving Aloe ferox the global podium it deserves. This is not just an agricultural oversight; it is a glaring economic misstep.

Aloe ferox could be a flagship in the global wellness market, much like rooibos has become for tea. But until we embrace and promote our indigenous resources with the same vigour as we do foreign ones, our ‘green gold’ will remain just out of reach, a latent promise unfulfilled. It’s high time South Africa capitalise and turn the tables on international competitors, finally giving Aloe ferox the global podium it deserves,” said Dr Verhoef.

The path forward, he explains, requires a radical shift in how we view and value our native species. It demands a coalition of dedicated scientists, legal advisers, and farmers to advocate for more accommodating regulations and stronger market support. The pharmaceutical and cosmetic industries – major users of aloe products – must also be brought into the fold to help recalibrate the scales in favour of Aloe ferox. South Africa’s rich biodiversity is a national treasure, yet our approach to leveraging this wealth remains timid and fragmented.

News Archive

UFS cardiac team leading with project
2017-05-31

 Description: Cardiac team read more Tags: Cardiac team read more

Prof Peter Schultheiss of the Charité University in Berlin,
Germany, visited the Robert WM Frater Centre for
Cardiovascular Research at the UFS for a study regarding
cardiomyopathy, a significant cause of fatal heart failure
among Africans. From the left are Dr Glen Taylor,
Dr Danie Buys, Prof Makoali Makatoko,
Prof Schultheiss and Prof Francis Smit.
Photo: Rulanzen Martin

A team of cardiac doctors associated with the Robert WM Frater Cardiovascular Research Centre at the University of the Free State’s (UFS) Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.  

An Afrocentric research focus
Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition and 50% of patients that have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made where virus infections of the heart muscle or myocarditis have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

International collaborations ensure success
According to Prof Smit, the project is being run in conjunction with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

“We have been working on the project over the past 18 months and I have twice visited Prof Schultheiss in Germany. He is now visiting us in Bloemfontein. We have established a collaborative project focused on patients in central South Africa”.
Prof Schultheiss is a world leader regarding the diagnosis, pathology and treatment of dilating cardiomyopathy, says Prof Smit.

“He brings a lifetime of research experience to Bloemfontein and is internationally renowned as the father of myocardial or heart muscle biopsies.

“His pioneering work on the discipline has led to diagnostic accuracy that has induced purposeful and personalised treatment of dilating cardiomyopathy and has brought about dramatic changes in some subsets of patients’ life expectancy and their cure.”

Solving problems close to home
According to Prof Mokoali Makatoko, Head of the Department of Cardiology, there are more than 1500 new cases of heart failure identified annually at the Universitas Academic Hospital, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies the team hopes to treat viruses unique to Southern Africa as well as other underlying causes of dilating cardiomyopathy.”

Prof Stephen Brown, Head of Paediatric Cardiology at the Universitas Academic Hospital, says children suffering from this disease never reach a mature age and those under his supervision will also be undergoing these tests. Various other departments at the UFS will also participate in this project. Profs Makatoko and Brown did the first four endomyocardial biopsies under the management of Prof Schultheiss during the past week. The results will be available in the coming weeks after which the project will be officially launched and patient recruitment will start in earnest.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept